These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 22385314)

  • 21. Storage-Induced Platelet Apoptosis Is a Potential Risk Factor for Alloimmunization Upon Platelet Transfusion.
    Saris A; Peyron I; van der Meer PF; Stuge TB; Zwaginga JJ; van Ham SM; Ten Brinke A
    Front Immunol; 2018; 9():1251. PubMed ID: 29951051
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New paradigms in the management of alloimmune refractoriness to platelet transfusions.
    Vassallo RR
    Curr Opin Hematol; 2007 Nov; 14(6):655-63. PubMed ID: 17898571
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of universal vs bedside leukoreductions on the alloimmunization to platelets and the platelet transfusion refractoriness.
    Mishima Y; Tsuno NH; Matsuhashi M; Yoshizato T; Sato T; Ikeda T; Watanabe-Okochi N; Nagura Y; Sone S; Kurokawa M; Okazaki H
    Transfus Apher Sci; 2015 Feb; 52(1):112-21. PubMed ID: 25467707
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alloimmune refractoriness to platelet transfusions.
    Sandler SG
    Curr Opin Hematol; 1997 Nov; 4(6):470-3. PubMed ID: 9359008
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rituximab, plasma exchange and intravenous immunoglobulins as a new treatment strategy for severe HLA alloimmune platelet refractoriness.
    Cid J; Magnano L; Acosta M; Alba C; Esteve J; Lozano M
    Platelets; 2015; 26(2):190-4. PubMed ID: 24867634
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sensitization by platelet transfusion.
    Brand A
    Schweiz Med Wochenschr; 1991 Mar; 121(13):467-9. PubMed ID: 2031162
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Efficacy of leukocyte-depleted platelet concentrates for prevention of HLA-alloimmunization in patients with frequent platelet transfusions: a prospective multi-institutional study using a polyester platelet filter].
    Handa M; Ikeda Y; Kurata Y; Tsubaki K; Horiuchi A; Furihata K; Kimura Y; Toyama K; Takamoto S; Tsukimoto I
    Rinsho Ketsueki; 1992 Apr; 33(4):451-60. PubMed ID: 1602608
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical and laboratory factors underlying refractoriness to platelet transfusions.
    Friedberg RC
    J Clin Apher; 1996; 11(3):143-8. PubMed ID: 8915819
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Platelet transfusion therapy.
    Slichter SJ
    Hematol Oncol Clin North Am; 2007 Aug; 21(4):697-729, vii. PubMed ID: 17666286
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune responsiveness against allogeneic platelet transfusions is determined by the recipient's major histocompatibility complex class II phenotype.
    Sayeh E; Aslam R; Speck ER; Le-Tien H; Lazarus AH; Freedman J; Semple JW
    Transfusion; 2004 Nov; 44(11):1572-8. PubMed ID: 15504162
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The leukodepletion of cellular blood products in the prevention of HLA-alloimmunization and refractoriness to allogeneic platelet transfusions.
    Heddle NM; Blajchman MA
    Blood; 1995 Feb; 85(3):603-6. PubMed ID: 7833464
    [No Abstract]   [Full Text] [Related]  

  • 32. Clinical relevance of the HLA system in blood transfusion.
    Brown CJ; Navarrete CV
    Vox Sang; 2011 Aug; 101(2):93-105. PubMed ID: 21535436
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunological platelet transfusion refractoriness: current insights from mechanisms to therapeutics.
    Chen X; Zhao Y; Lv Y; Xie J
    Platelets; 2024 Dec; 35(1):2306983. PubMed ID: 38314765
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The alloimmunized patient: effective transfusion support and newer experimental approaches.
    Pamphilon DH
    Blood Coagul Fibrinolysis; 1992 Oct; 3(5):651-4. PubMed ID: 1450334
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human leukocyte antigen alloimmunization prevention mechanisms in blood transfusion.
    Adane T; Enawgaw B
    Asian J Transfus Sci; 2023; 17(2):264-272. PubMed ID: 38274979
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevention of HLA alloimmunization: role of leukocyte depletion and UV-B irradiation.
    Snyder EL
    Yale J Biol Med; 1990; 63(5):419-27. PubMed ID: 2293501
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Prevention of platelet transfusion refractoriness and HLA alloimmunization by leukocyte filtered platelet transfusion: a meta analysis].
    Yuan Q; Chen X; Cheng L; Zhou CH; Fu XM; Li YP; Wang NH; Wang L
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2011 Aug; 33(4):412-20. PubMed ID: 21906451
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevention of alloimmunization in patients with acute leukemia by use of white cell-reduced blood components--a randomized trial.
    Oksanen K; Kekomäki R; Ruutu T; Koskimies S; Myllylä G
    Transfusion; 1991 Sep; 31(7):588-94. PubMed ID: 1891788
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune modulation and lack of alloimmunization following transfusion with pathogen-reduced platelets in mice.
    Jackman RP; Muench MO; Heitman JW; Inglis HC; Law JP; Marschner S; Goodrich RP; Norris PJ
    Transfusion; 2013 Nov; 53(11):2697-709. PubMed ID: 23451715
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Platelet transfusion refractoriness.
    Hod E; Schwartz J
    Br J Haematol; 2008 Jul; 142(3):348-60. PubMed ID: 18510692
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.